Baird analyst David Rescott lowered the firm’s price target on Inspire Medical to $236 from $250 and keeps an Outperform rating on the shares. The firm thinks the recent sell-off creates an attractive opportunity for investors with a 6-12-month view as the company continues to penetrate the large/undertreated opportunity.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INSP:
- Inspire Medical raises FY23 revenue view to $608M-$612M from $600M-$610M
- Inspire Medical reports Q3 EPS (29c), consensus (58c)
- Inspire Medical price target lowered to $250 from $350 at Stifel
- LivaNova price target lowered to $62 from $71 at Needham
- Inspire Medical price target lowered to $180 from $355 at BofA